Amphotericin B liposomal contraindications: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Amphotericin B liposomal}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMBISOME (AMPHOTERICIN B) INJECTION...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Contraindications== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMBISOME (AMPHOTERICIN B) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a | publisher = | date = | accessdate = }}</ref> | AmBisome is contraindicated in those patients who have demonstrated or have known hypersensitivity to amphotericin B deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = AMBISOME (AMPHOTERICIN B) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 15:49, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
AmBisome is contraindicated in those patients who have demonstrated or have known hypersensitivity to amphotericin B deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.[1]
References
Adapted from the FDA Package Insert.